JP2009515949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515949A5 JP2009515949A5 JP2008541107A JP2008541107A JP2009515949A5 JP 2009515949 A5 JP2009515949 A5 JP 2009515949A5 JP 2008541107 A JP2008541107 A JP 2008541107A JP 2008541107 A JP2008541107 A JP 2008541107A JP 2009515949 A5 JP2009515949 A5 JP 2009515949A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- heteroaryl
- heteroarylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 86
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 82
- 125000000753 cycloalkyl group Chemical group 0.000 claims 73
- 125000003118 aryl group Chemical group 0.000 claims 72
- 125000001072 heteroaryl group Chemical group 0.000 claims 71
- 125000003710 aryl alkyl group Chemical group 0.000 claims 70
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 70
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 58
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 58
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 54
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 53
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 40
- 125000005843 halogen group Chemical group 0.000 claims 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 238000001727 in vivo Methods 0.000 claims 5
- 239000002243 precursor Substances 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- PFWVTHUDSZRCTO-UHFFFAOYSA-N 2-amino-1-methyl-5-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1N=C(N)N(C)C=C1CCC1=CC=CC=C1 PFWVTHUDSZRCTO-UHFFFAOYSA-N 0.000 claims 1
- QRZKQTGJCKDSGN-UHFFFAOYSA-N 2-amino-3,5-dimethyl-6-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC=C1 QRZKQTGJCKDSGN-UHFFFAOYSA-N 0.000 claims 1
- UMPOTDYQEMLZRZ-UHFFFAOYSA-N 2-amino-3-methyl-5-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1N(C)C(N)=NC=C1CCC1=CC=CC=C1 UMPOTDYQEMLZRZ-UHFFFAOYSA-N 0.000 claims 1
- NTOOSRIQBIMWSJ-UHFFFAOYSA-N 2-amino-3-methyl-5-phenyl-6-(2-phenylethyl)pyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1C=1C(=O)N(C)C(N)=NC=1CCC1=CC=CC=C1 NTOOSRIQBIMWSJ-UHFFFAOYSA-N 0.000 claims 1
- MALAKURYZJFBLT-UHFFFAOYSA-N 2-amino-3-methyl-6-(2-phenylethyl)pyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(CCC=2C=CC=CC=2)=C1 MALAKURYZJFBLT-UHFFFAOYSA-N 0.000 claims 1
- NEKSSFOSVQFARB-UHFFFAOYSA-N 2-amino-4-(3-bromo-4-chlorophenyl)-4,5-dimethyl-1,5-dihydropyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1C(=O)NC(N)=NC1(C)C1=CC=C(Cl)C(Br)=C1 NEKSSFOSVQFARB-UHFFFAOYSA-N 0.000 claims 1
- GZPIUMLCUOIOIU-UHFFFAOYSA-N 2-amino-5-(2-phenylethyl)-1h-pyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1NC(N)=NC=C1CCC1=CC=CC=C1 GZPIUMLCUOIOIU-UHFFFAOYSA-N 0.000 claims 1
- XMKDVXUWXNFCOG-UHFFFAOYSA-N 2-amino-5-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-1h-pyrimidin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC=3C(NC(N)=NC=3)=O)C=CC=2)=C1 XMKDVXUWXNFCOG-UHFFFAOYSA-N 0.000 claims 1
- PLXBBXSHAWKMPQ-UHFFFAOYSA-N 2-amino-5-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC=3C(N(C)C(N)=NC=3)=O)C=CC=2)=C1 PLXBBXSHAWKMPQ-UHFFFAOYSA-N 0.000 claims 1
- UJZKVDNGADIRTE-UHFFFAOYSA-N 2-amino-5-benzyl-6-[2-(3-bromophenyl)ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CC=1C(=O)N(C)C(N)=NC=1CCC1=CC=CC(Br)=C1 UJZKVDNGADIRTE-UHFFFAOYSA-N 0.000 claims 1
- HUUIHHSBUQUGQT-UHFFFAOYSA-N 2-amino-5-benzyl-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3=C(C(=O)N(C)C(N)=N3)CC=3C=CC=CC=3)C=CC=2)=C1 HUUIHHSBUQUGQT-UHFFFAOYSA-N 0.000 claims 1
- BVQRDQHLQSWFKK-UHFFFAOYSA-N 2-amino-5-bromo-3-methyl-6-(2-phenylethyl)pyrimidin-4-one Chemical compound O=C1N(C)C(N)=NC(CCC=2C=CC=CC=2)=C1Br BVQRDQHLQSWFKK-UHFFFAOYSA-N 0.000 claims 1
- CNBSPUGFNQVSJS-UHFFFAOYSA-N 2-amino-6-(2-phenylethyl)-1h-pyrimidin-4-one Chemical compound N1C(N)=NC(=O)C=C1CCC1=CC=CC=C1 CNBSPUGFNQVSJS-UHFFFAOYSA-N 0.000 claims 1
- BSFYBPPWNXZIPH-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-1h-pyrimidin-4-one Chemical compound O=C1NC(N)=NC(CCC=2C=C(Br)C=CC=2)=C1 BSFYBPPWNXZIPH-UHFFFAOYSA-N 0.000 claims 1
- QZJVGUKULLSSCO-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-3,5-dimethylpyrimidin-4-one Chemical compound N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(Br)=C1 QZJVGUKULLSSCO-UHFFFAOYSA-N 0.000 claims 1
- MUWOCUNRCCSVTE-UHFFFAOYSA-N 2-amino-6-[2-(3-bromophenyl)ethyl]-5-methyl-1h-pyrimidin-4-one Chemical compound N1=C(N)NC(=O)C(C)=C1CCC1=CC=CC(Br)=C1 MUWOCUNRCCSVTE-UHFFFAOYSA-N 0.000 claims 1
- DTBQCGNZLPFKJS-UHFFFAOYSA-N 2-amino-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3=C(C(=O)N(C)C(N)=N3)C)C=CC=2)=C1 DTBQCGNZLPFKJS-UHFFFAOYSA-N 0.000 claims 1
- SXFTZSKTVNASQO-UHFFFAOYSA-N 2-amino-6-[2-[3-(furan-2-yl)phenyl]ethyl]-3,5-dimethylpyrimidin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)N(C)C(=O)C(C)=C1CCC1=CC=CC(C=2OC=CC=2)=C1 SXFTZSKTVNASQO-UHFFFAOYSA-N 0.000 claims 1
- VDDYOHIPPWWPQC-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-3,8-dimethyl-6,7-dihydro-5h-quinazolin-4-one Chemical compound O=C1N(C)C(N)=NC2=C1CCCC2(C)CC1=CC=CC(Br)=C1 VDDYOHIPPWWPQC-UHFFFAOYSA-N 0.000 claims 1
- NXTSOXXYMHVMIN-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-3-methyl-5,6,7,8-tetrahydroquinazolin-4-one Chemical compound C1CCC=2C(=O)N(C)C(N)=NC=2C1CC1=CC=CC(Br)=C1 NXTSOXXYMHVMIN-UHFFFAOYSA-N 0.000 claims 1
- YAVQQCQABYEAMN-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-5,6,7,8-tetrahydro-1h-quinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=2NC(N)=NC(=O)C=2CCCC1CC1=CC=CC(Br)=C1 YAVQQCQABYEAMN-UHFFFAOYSA-N 0.000 claims 1
- XKOANOLURVHUGM-UHFFFAOYSA-N 2-amino-8-[(3-bromophenyl)methyl]-8-methyl-1,5,6,7-tetrahydroquinazolin-4-one Chemical compound C1CCC(C(NC(N)=N2)=O)=C2C1(C)CC1=CC=CC(Br)=C1 XKOANOLURVHUGM-UHFFFAOYSA-N 0.000 claims 1
- QDUPIWKQAWTULW-UHFFFAOYSA-N 2-amino-8-[[3-(3-methoxyphenyl)phenyl]methyl]-3,8-dimethyl-6,7-dihydro-5h-quinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CC3(C)C4=C(C(N(C)C(N)=N4)=O)CCC3)C=CC=2)=C1 QDUPIWKQAWTULW-UHFFFAOYSA-N 0.000 claims 1
- OPBNBRSINBFTFT-UHFFFAOYSA-N 2-amino-8-[[3-(3-methoxyphenyl)phenyl]methyl]-3-methyl-5,6,7,8-tetrahydroquinazolin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CC3C4=C(C(N(C)C(N)=N4)=O)CCC3)C=CC=2)=C1 OPBNBRSINBFTFT-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 *C1=C(*)N=C(N)N(*)C1=O Chemical compound *C1=C(*)N=C(N)N(*)C1=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73732605P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/001280 WO2007058580A1 (en) | 2005-11-15 | 2006-11-13 | Novel 2-aminopyrimidinone derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515949A JP2009515949A (ja) | 2009-04-16 |
| JP2009515949A5 true JP2009515949A5 (enExample) | 2010-01-07 |
Family
ID=38048893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541107A Pending JP2009515949A (ja) | 2005-11-15 | 2006-11-13 | 新規な２−アミノピリミジノン誘導体およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090215801A9 (enExample) |
| EP (1) | EP1951680A4 (enExample) |
| JP (1) | JP2009515949A (enExample) |
| CN (1) | CN101360720A (enExample) |
| WO (1) | WO2007058580A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2609582A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| WO2007049532A1 (ja) | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | アミノジヒドロチアジン誘導体 |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| RU2476430C2 (ru) | 2007-04-24 | 2013-02-27 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина, замещенные циклической группой |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| BRPI0915500A2 (pt) | 2008-06-13 | 2019-08-27 | Shionogi & Co | derivado heterocíclico contendo enxofre tendo atividade inibitória de beta secretase |
| MX2011002613A (es) | 2008-09-11 | 2011-05-23 | Pfizer | Derivados de heteroarilamida y su uso como activadores de glucoquinasa. |
| EP2360155A4 (en) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| WO2010084428A1 (en) | 2009-01-20 | 2010-07-29 | Pfizer Inc. | Substituted pyrazinone amides |
| HRP20130661T1 (en) | 2009-03-11 | 2013-08-31 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
| EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| BR112012008795A2 (pt) | 2009-10-16 | 2020-09-24 | Rib-X Pharmaceuticals, Inc. | compostos antimicrobianos e métodos de fabricação e uso dos mesmos. |
| JP6274723B2 (ja) | 2009-10-16 | 2018-02-07 | メリンタ セラピューティクス，インコーポレイテッド | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
| BR112012013854A2 (pt) | 2009-12-11 | 2019-09-24 | Shionogi & Co | derivados de oxazina. |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| WO2012057247A1 (ja) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| WO2013066729A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| MX2016003046A (es) | 2013-09-09 | 2016-09-08 | Melinta Therapeutics Inc | Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos. |
| CA2923214A1 (en) | 2013-09-09 | 2015-03-12 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| JP2018507881A (ja) | 2015-03-11 | 2018-03-22 | メリンタ セラピューティクス，インコーポレイテッド | 抗微生物化合物ならびにこれらを作製および使用する方法 |
| US11098047B2 (en) | 2016-05-06 | 2021-08-24 | BioVersys AG | Antimicrobials and methods of making and using same |
| WO2020163689A1 (en) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4625026A (en) * | 1982-12-30 | 1986-11-25 | Biomeasure, Inc. | 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections |
| EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| HUP0300029A2 (en) * | 2000-02-25 | 2003-05-28 | Hoffmann La Roche | Adenosine receptor modulators, pharmaceutical compositions containing them and their use |
| US20030114445A1 (en) * | 2001-06-15 | 2003-06-19 | Chengxin Zhi | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections |
| US6777420B2 (en) * | 2001-06-15 | 2004-08-17 | Microbiotix, Inc. | Heterocyclic antibacterial compounds |
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| CN101671307B (zh) * | 2003-12-15 | 2014-05-14 | 默沙东公司 | 杂环天冬氨酰蛋白酶抑制剂 |
| US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| MX2007016182A (es) * | 2005-06-14 | 2008-03-07 | Schering Corp | Inhibidores de aspartil proteasas. |
| EP1902057B1 (en) * | 2005-06-14 | 2013-10-23 | Merck Sharp & Dohme Corp. | Macrocyclic heterocyclic aspartyl protease inhibitors |
| JP2009513656A (ja) * | 2005-10-27 | 2009-04-02 | シェーリング コーポレイション | 複素環式アスパルチルプロテアーゼインヒビター |
| PE20070798A1 (es) * | 2005-10-31 | 2007-08-24 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
-
2006
- 2006-11-13 US US12/093,670 patent/US20090215801A9/en not_active Abandoned
- 2006-11-13 CN CNA200680051085XA patent/CN101360720A/zh active Pending
- 2006-11-13 JP JP2008541107A patent/JP2009515949A/ja active Pending
- 2006-11-13 EP EP06813003A patent/EP1951680A4/en not_active Withdrawn
- 2006-11-13 WO PCT/SE2006/001280 patent/WO2007058580A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515949A5 (enExample) | ||
| EP2485920B1 (en) | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use | |
| US7425552B2 (en) | Pyridazinone compounds | |
| JP2013544893A5 (enExample) | ||
| WO2006033007A3 (en) | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | |
| CA2654405A1 (en) | Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia | |
| RU2013138717A (ru) | Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе | |
| JP2006522747A5 (enExample) | ||
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| CN101263130A (zh) | 2-苯胺-4-芳基取代的噻唑衍生物 | |
| JP2014526549A5 (enExample) | ||
| AU2007345526A2 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| JP2008500992A5 (enExample) | ||
| WO2007134107A3 (en) | Cold menthol receptor-1 antagonists | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| CA2981499A1 (en) | Methods of administering glutaminase inhibitors | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| ES2222396T3 (es) | Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas. | |
| JP2012530758A5 (enExample) | ||
| WO2007056219A3 (en) | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | |
| TW201540716A (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| CA2604017A1 (en) | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | |
| JP2017513887A5 (enExample) | ||
| JP2020503293A5 (enExample) | ||
| TWI616445B (zh) | 新穎環丙苯并呋喃基吡啶并吡二酮類 |